The occurrence of adverse events after receiving the first and second dose in the participants with underlying chronic disease.</p
Treatment-emergent adverse events (TEAEs) after the first dose in patients with ≥2 cardiovascular ri...
Other unlisted adverse effects associated with the first dose of COVID-19 vaccines.</p
<p>Serious adverse events in patients who completed all pharmacokinetic assessments (N = 25) and in ...
The occurrence of adverse events after receiving the first and second dose in the participants with ...
Adverse events following first and second immunization of COVID-19 among the participants.</p
<p>Treatment-emergent adverse events experienced by ≥3 patients in any treatment group in the Phase ...
Incidence of adverse events during on-treatment follow-up and whole study period.</p
<p>Number and percentages of subjects showing adverse events after administration of drugs in differ...
<p>Adverse events: local and systemic adverse events 21 days after first dose and 42 days after the ...
Adverse events (according to low-level term) reported in at least 10 patients during follow-up.</p
<p>Treatment-emergent adverse events experienced by ≥5% of patients in either treatment group (treat...
<p>Treatment-emergent adverse events occurring during the Phase I study in at least two different su...
Treatment-related adverse events occurring in ≥1% of the total population (SS).</p
The prevalence of side effects among participants in terms of demographic characteristics after firs...
The prevalence of side effects among participants in terms of demographic characteristics after firs...
Treatment-emergent adverse events (TEAEs) after the first dose in patients with ≥2 cardiovascular ri...
Other unlisted adverse effects associated with the first dose of COVID-19 vaccines.</p
<p>Serious adverse events in patients who completed all pharmacokinetic assessments (N = 25) and in ...
The occurrence of adverse events after receiving the first and second dose in the participants with ...
Adverse events following first and second immunization of COVID-19 among the participants.</p
<p>Treatment-emergent adverse events experienced by ≥3 patients in any treatment group in the Phase ...
Incidence of adverse events during on-treatment follow-up and whole study period.</p
<p>Number and percentages of subjects showing adverse events after administration of drugs in differ...
<p>Adverse events: local and systemic adverse events 21 days after first dose and 42 days after the ...
Adverse events (according to low-level term) reported in at least 10 patients during follow-up.</p
<p>Treatment-emergent adverse events experienced by ≥5% of patients in either treatment group (treat...
<p>Treatment-emergent adverse events occurring during the Phase I study in at least two different su...
Treatment-related adverse events occurring in ≥1% of the total population (SS).</p
The prevalence of side effects among participants in terms of demographic characteristics after firs...
The prevalence of side effects among participants in terms of demographic characteristics after firs...
Treatment-emergent adverse events (TEAEs) after the first dose in patients with ≥2 cardiovascular ri...
Other unlisted adverse effects associated with the first dose of COVID-19 vaccines.</p
<p>Serious adverse events in patients who completed all pharmacokinetic assessments (N = 25) and in ...
DOI
Add to ORKG